# SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

> **NCT03603756** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 45 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Apatinib
- **DRUG:** Irinotecan Injection
- **DRUG:** Paclitaxel liposome
- **DRUG:** Nedaplatin

## Key facts

- **NCT ID:** NCT03603756
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-31
- **Primary completion:** 2020-03-28
- **Final completion:** 2021-03-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603756, "SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03603756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*